Policy | April 03, 2026
EMA moves to cut animal testing with “virtual control groups” in preclinical research
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Subscribe To Our Newsletter & Stay Updated
